| Costos de la esclerosis múltiple en Colombia. | |
| | |
MedLine Citation:
|
PMID: 21839899 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
OBJECTIVE: To estimate, according to the states of disease (remission or relapse) and her level of progression (EDSS), the cost of treatment of Multiple Sclerosis (MS) in Colombia. METHODS: From the perspective of the third payer, a cost study of MS was performed using two-way estimation techniques: a) "Top down" to estimate the costs during relapses from clinical registers of 304 patients; b) "bottom-up" to estimate the cost in remission from a questionnaire (Kobelt 2006) applied to 137 patients, located in different regions of Colombia. RESULTS: The mean of patient's age was 43,7 years and 73% of those were women. The mean annual cost per patient varied according to the disease phase, finding the highest value in Phase II (EDSS 3 - 5,5) with $ 50.581.216 COP (US$ 25.713) and the lowest one in Phase IV (EDSS 8 - 9,5) with $20.738.845 COP (US$ 10.543). The cost of Disease Modifier Drugs (DMD) represented 91.5% from the medial total annual cost of 1,2 and 3 phases. The participation of DMD was 58%.in the 4 phase. Indirect costs are minimal participation in all phases, except for 4 where increases at the expense of reduced consumption of DMD. Costs associated with the period of relapses of MS are low against the total cost, with an average cost of $ 2,433,182 COP ($ 1.237USD). DISCUSSION: MS in Colombia is a disease with a behavioral pathology "high cost " to the social security system (SGSSS), generated mainly at the expense of their direct costs, which, even without including relapses, an aggregate amount of more than 75 times the annual premium cost of health insurance for Colombia ($ 430,488 COP) in the year under review (2008). |
| | |
Authors:
|
Martin Romero; Carlos Arango; Nelson Alvis; Juan Camilo Suarez; Aristides Duque |
Related Documents
:
|
21910299 - Social security disability beneficiaries with work-related goals and expectations. 18479529 - The effect of ambient air pollution on respiratory health of school children: a panel s... 8353009 - Death certification by house officers and general practitioners--practice and performance. 14531969 - Modification of provider behavior to achieve improved asthma outcomes. 19054949 - Bringing nature to the fore. 19807599 - Teachable moments: improving pediatric asthma outcomes through physician education. 7790289 - Electrocortical, autonomic, and subjective responses to rhythmic audio-visual stimulation. 22033049 - Use of simulation-based education to improve resident learning and patient care in the ... 8593529 - Blood product costing: relationship to price and clinical efficacy. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research Volume: 14 ISSN: 1524-4733 ISO Abbreviation: Value Health Publication Date: 2011 Jul-Aug |
Date Detail:
|
Created Date: 2011-08-15 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 100883818 Medline TA: Value Health Country: United States |
Other Details:
|
Languages: eng Pagination: S48-50 Citation Subset: IM |
Copyright Information:
|
Copyright © 2011 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved. |
Affiliation:
|
Fundación Salutia Centro de investigaciones económicas, de gestión y tecnologías en salud, Bogotá, Colombia. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Costo-Efectividad del Tratamiento de Salmeterol/Fluticasona en Comparación con Leucotrieno Monteluk...
Next Document: Development and validation of a microsimulation economic model to evaluate the disease burden associ...